Results 231 to 240 of about 87,328 (317)

Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark. [PDF]

J Neurol Neurosurg Psychiatry
von Kappelgaard L, Framke E, Vassard D, Pinborg A, Schwarze JE, Sabidó M, Magyari M.   +6 more
europepmc   +1 more source

Integrating real‐world data with gold‐standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof‐of‐concept data platform

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Integrating real‐world data (RWD) with clinical research datasets creates more complete, context‐rich resources to drive discovery and enable precision medicine in Alzheimer's disease and related dementias. The National Alzheimer's Coordinating Center conducted a proof‐of‐concept (POC) project to link its longitudinal Uniform Data
Sarah Biber, Jessica E. Culhane, Maria G. Prado, Satish Mathew, Yohali Burrola‐Mendez, Imara I. West, Sarah Van Heiden, Jimmy Phuong, Shilpa Allimatti, Liam G. Lane, Krista L. Moulder, Brittany K. Hale, Amanda Kuzma, Li‐San Wang, Sujuan Gao, Albert Lai, Karthik Natarajan, Sophia Wang, John C. Morris, James M. Noble, Sean D. Mooney, Walter Kukull, Andrew J. Saykin, Kari A. Stephens   +23 more
wiley   +1 more source

From diagnosis to treatment: patterns in disease-modifying therapy initiation in multiple sclerosis. [PDF]

Ther Adv Neurol Disord
Iaquinto S, Stanikić M, Vallejo-Yagüe E, Kuhle J, Manjaly ZM, Roth P, Calabrese P, Zecca C, Puhan MA, von Wyl V.   +9 more
europepmc   +1 more source

Alpha‐synuclein co‐pathology in a real‐world early Alzheimer's disease cohort

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract BACKGROUND Most Alzheimer's disease (AD) cases show mixed pathology, with α‐synuclein (αSyn) aggregates present in a substantial proportion. The cerebrospinal fluid (CSF) α‐synuclein seed amplification assay (αS‐SAA) enables in vivo detection of pathogenic αSyn aggregates, but its clinical significance remains unclear. METHODS We prospectively
Tamara Shiner, Talya Nathan, Mori Hai Levy, Aya Bar David, Nurit Omer, Anan Abu Awad, Elissa Ash, Mali Gana Weisz, Orly Goldstein, Yifat Alcalay, Keren Regev, Jennifer Lamoureux, Kendall Van Keuren‐Jensen, Cornelis Blauwendraat, Roy N Alcalay, Noa Bregman   +15 more
wiley   +1 more source

Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice. [PDF]

Ther Adv Neurol Disord
Zanghì A, Borriello G, Foschi M, Bianco A, Signoriello E, Cellerino M, Di Filippo PS, Baldisseri F, Romano G, Cicia A, Lus G, Inglese M, Mirabella M, Avolio C, D'Amico E.   +14 more
europepmc   +1 more source

Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

Annals of Neurology, Volume 99, Issue 3, Page 715-729, March 2026.
Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric
Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Kimberly O'Neill, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, John Rose, Alice Rutatangwa, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, Kristen M. Krysko, on behalf of the US Network of Pediatric MS Centers   +27 more
wiley   +1 more source

Transmembrane Transport of cAMP and AMP Using a Two Component Small Molecule Transport System. [PDF]

Angew Chem Int Ed Engl
Rathnaweera UMC, Sam O, Norvaisa K, Marshall SR, Weerakonda Arachchige RDS, Chvojka M, Valkenier H, Busschaert N.   +7 more
europepmc   +1 more source

Cost‐effectiveness and impact at scale of collaborative care and lecanemab for Alzheimer's disease

Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 1, March 2026.
Abstract INTRODUCTION Advancements in disease‐modifying therapies and collaborative dementia care programs have created opportunities to transform care for people with Alzheimer's disease. METHODS We modeled people aged 71 across three scenarios: 18 months of lecanemab, collaborative care, and combined interventions.
Kelly J. Atkins, James G. Kahn, Katherine L. Possin   +2 more
wiley   +1 more source

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways. [PDF]

Sci Rep
Lima G, Soares C, Teixeira M, Pais M, Cabral C, Rijo P, Castelo-Branco M.   +6 more
europepmc   +1 more source

Psychosocial interventions to increase social participation for people with dementia living in the community: A systematic review

Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 1, March 2026.
Abstract Less social participation may cause adverse outcomes for people with dementia, but it remains unclear whether existing interventions are effective. We therefore systematically identified interventions aiming to improve social participation for community‐dwelling people with dementia. Across 15 controlled trials (n = 1965) comprising nine (60%)
Zuyu Wang, Gill Livingston, Puyu Shi, Fern Rodgers, Angela Hassiotis, Andrew Sommerlad   +5 more
wiley   +1 more source